News from ohr pharmaceutical inc

Aug 09, 2013, 09:10 ET

Ohr Pharmaceutical to Present at the Wedbush Life Sciences Management Access Conference on August 14th

 Ohr Pharmaceutical (NasdaqCM: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Aug 07, 2013, 09:00 ET

Ohr Pharmaceutical Announces Addition of Dr. John Wroblewski to Ophthalmic Scientific Advisory Board

Ohr Pharmaceutical Inc. (NasdaqCM: OHRP) today announced the addition of John J. Wroblewski M.D. to its Scientific Advisory Board ("SAB"). The...

Jul 10, 2013, 06:55 ET

Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial

Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Jun 12, 2013, 06:55 ET

Ohr Pharmaceutical Announces Approval for Listing on NASDAQ

 Ohr Pharmaceutical, Inc. (OTCQB: OHRPD), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical...

Jun 03, 2013, 06:55 ET

Ohr Pharmaceutical Announces Reverse Split of Common Stock

 Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical...

May 29, 2013, 12:33 ET

Ohr Pharmaceutical to Present at the Marcum MicroCap Conference on May 30th

Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today...

May 22, 2013, 08:30 ET

Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors

 Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs,...

May 02, 2013, 07:00 ET

Ohr Pharmaceutical Appoints Thomas M. Riedhammer To Board Of Directors

 Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs,...

Apr 22, 2013, 07:00 ET

Ohr Pharmaceutical Announces $5 Million Financing from Exercise of Warrants

 Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs,...

Mar 21, 2013, 06:30 ET

Ohr Pharmaceutical Announces Results from OHR/AVR118 Phase II Trial in Cancer Cachexia

 Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Feb 07, 2013, 09:15 ET

Ohr Pharmaceutical to Present at 15th Annual BIO CEO & Investor Conference

 Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical...

Jan 03, 2013, 09:15 ET

Ohr Pharmaceutical To Present At Biotech Showcase 2013 in San Francisco

  Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Dec 27, 2012, 09:15 ET

Ohr Pharmaceutical Provides Update to Shareholders on 2012 Accomplishments and Milestones for 2013

 Ohr Pharmaceutical Inc., a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in...

Nov 20, 2012, 08:15 ET

Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board

 Ohr Pharmaceutical Inc. (OTCBB: OHRP) today announced the addition of two prominent ophthalmologists to its Scientific Advisory Board ("SAB")...

Oct 05, 2012, 09:20 ET

Ohr Pharmaceutical to Present at the 11th Annual BIO Investor Forum

 Ohr Pharmaceutical (OTCBB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Sep 24, 2012, 08:10 ET

Ohr Pharmaceutical Initiates Phase II Trial of Squalamine Eye Drops For The Treatment Of Wet Macular Degeneration

 Ohr Pharmaceutical (OTCBB: OHRP-News) today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer